Marschall H U, Matern H, Wietholtz H, Egestad B, Matern S, Sjövall J
Department of Internal Medicine III, Aachen University of Technology, Germany.
J Clin Invest. 1992 Jun;89(6):1981-7. doi: 10.1172/JCI115806.
The aim of this study was to define whether N-acetylglucosaminidation is a selective conjugation pathway of structurally related bile acids in humans. The following bile acids released enzymatically from N-acetylglucosaminides were identified: 3 alpha,7 beta-dihydroxy-5 beta-cholanoic (ursodeoxycholic), 3 beta, 7 beta-dihydroxy-5 beta-cholanoic (isoursodeoxycholic), 3 beta,7 beta-dihydroxy-5 alpha-cholanoic (alloisoursodeoxycholic), 3 beta,7 beta-dihydroxy-5-cholenoic, 3 alpha,7 beta,12 alpha-trihydroxy-5 beta-cholanoic, and 3 alpha,6 alpha,7 beta-trihydroxy-5 beta-cholanoic acids. The selectivity of conjugation was studied by administration of 0.5 g ursodeoxycholic (UDCA) or hyodeoxycholic (HDCA) acids, labeled with 13C, to patients with extrahepatic cholestasis, and of 0.5 g of 13C-labeled chenodeoxycholic acid (CDCA) to patients with extra- or intrahepatic cholestasis. After administration of [24-13C]-CDCA, labeled glucosides, and the glucuronide of CDCA were excreted in similar amounts. Labeled N-acetylglucosaminides of UDCA and isoUDCA were also formed. When [24-13C]-UDCA was given, 13C-label was detected in the N-acetylglucosaminide, the glucosides, and the glucuronide of UDCA, and in the N-acetylglucosaminide of isoUDCA. In the patient studied, 32% of the total UDCA excreted in urine was conjugated with N-acetylglucosamine. In contrast, 96% of the excreted amount of [24-13C]HDCA was glucuronidated, and 13C-labeled glucosides but no N-acetylglucosaminide were detected. The selectivity of N-acetylglucosaminidation towards bile acids containing a 7 beta-hydroxyl group was confirmed in vitro using human liver and kidney microsomes and uridine diphosphate glucose (UDP)-N-acetylglucosamine. These studies show that N-acetylglucosaminidation is a selective conjugation pathway for 7 beta-hydroxylated bile acids.
本研究的目的是确定N-乙酰葡糖胺化是否是人类中结构相关胆汁酸的一种选择性结合途径。从N-乙酰葡糖胺化物中酶促释放出的下列胆汁酸被鉴定出来:3α,7β-二羟基-5β-胆烷酸(熊去氧胆酸)、3β,7β-二羟基-5β-胆烷酸(异熊去氧胆酸)、3β,7β-二羟基-5α-胆烷酸(别异熊去氧胆酸)、3β,7β-二羟基-5-胆烯酸、3α,7β,12α-三羟基-5β-胆烷酸和3α,6α,7β-三羟基-5β-胆烷酸。通过给肝外胆汁淤积患者服用0.5 g用13C标记的熊去氧胆酸(UDCA)或猪去氧胆酸(HDCA),以及给肝外或肝内胆汁淤积患者服用0.5 g 13C标记的鹅去氧胆酸(CDCA),研究结合的选择性。给予[24-13C]-CDCA后,标记的葡糖苷和CDCA的葡糖醛酸苷以相似的量排泄。UDCA和异UDCA的标记N-乙酰葡糖胺化物也形成了。给予[24-13C]-UDCA时,在UDCA的N-乙酰葡糖胺化物、葡糖苷和葡糖醛酸苷以及异UDCA的N-乙酰葡糖胺化物中检测到13C标记。在所研究的患者中,尿中排泄的总UDCA中有32%与N-乙酰葡糖胺结合。相比之下,排泄的[24-13C]HDCA中有96%被葡糖醛酸化,并且检测到13C标记的葡糖苷,但未检测到N-乙酰葡糖胺化物。使用人肝和肾微粒体以及尿苷二磷酸葡萄糖(UDP)-N-乙酰葡糖胺在体外证实了N-乙酰葡糖胺化对含有7β-羟基的胆汁酸的选择性。这些研究表明,N-乙酰葡糖胺化是7β-羟基化胆汁酸的一种选择性结合途径。